Publication | Closed Access

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

OncologyMedicineIpilimumab-refractory Advanced MelanomaImmunologyMelanomaCell DeathImmune Checkpoint InhibitorPharmacotherapyCancer TreatmentImmunotherapyPharmacologyPhase 1Anti-programmed-death-receptor-1 Treatment